Kazia Therapeutics (KZIA) vs Milestone Pharmaceuticals (MIST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Kazia Therapeutics (KZIA) has outperformed Milestone Pharmaceuticals (MIST) over the past year, gaining 24.4% versus a loss of 63.4%. Over five years, MIST leads with a -87.0% price change compared with -98.3% for KZIA. Kazia Therapeutics is the larger company by market cap ($102.0 million vs $95.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KZIA | MIST |
|---|---|---|
| Share price | $8.93 | $0.765 |
| Market cap | $102.04M | $95.24M |
| 1-day change | +1.25% | +7.43% |
| YTD return | +29.61% | -62.13% |
| 1-year return | +24.37% | -63.40% |
| 5-year return | -98.30% | -87.03% |
| EPS (TTM) | $-6.85 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.40 | $3.06 |
| 52-week low | $4.86 | $0.7075 |
| Distance from 52-week high | -48.68% | -75.00% |
| Analyst consensus | none | none |
| Avg. price target upside | +216.46% | +666.01% |
| Average volume | 262.75K | 1.40M |
| Shares outstanding | 11.43M | 124.50M |
| Employees | 6 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KZIA has outperformed MIST by 87.8 percentage points over the past year.
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
KZIA vs MIST FAQ
Which is bigger, Kazia Therapeutics or Milestone Pharmaceuticals?
Kazia Therapeutics (KZIA) is larger, with a market capitalization of $102.04M compared with $95.24M for Milestone Pharmaceuticals (MIST).
Which stock has performed better over the past year, KZIA or MIST?
KZIA returned +24.37% over the past 12 months, compared with -63.40% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Kazia Therapeutics and Milestone Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.